<div id="readability-page-1"><div><p>(MT Newswires) -- Hubei Jumpcan Pharmaceutical (SHA:600566), through unit Shaanxi Dongke Pharmaceutical, obtained a drug registration certificate from the Chinese drug administration for its lidocaine cataplasms, according to a Shanghai bourse filing on Wednesday.</p><p> The product is an amide local anesthetic that stabilizes nerve cell membranes.</p><p>The certificate is valid until Sept. 8, 2030, the Chinese drug maker said.</p></div></div>

济川药业

<p>（MT Newswires）-- 湖北济川药业（SHA:600566）通过其子公司陕西东科药业，获得了中国药品监督管理局颁发的利多卡因膏药的药品注册证书，具体信息在周三的上海证券交易所公告中披露。该产品是一种酰胺类局部麻醉剂，能够稳定神经细胞膜。中国药企表示，该证书有效期至 2030 年 9 月 8 日</p>

济川药业获得了利多卡因贴剂的注册证书